Urine drug testing of chronic pain patients. III. normetabolites as biomarkers of synthetic opioid use

Anne De Priest, Rebecca Heltsley, David L. Black, Beverly Cawthon, Tim Robert, Frank Moser, Yale H. Caplan, Edward J. Cone

Research output: Contribution to journalArticle

Abstract

Opioids are important therapeutic agents available to patients with moderate to severe pain. The synthetic opioids, buprenorphine, fentanyl, meperidine, methadone, and propoxyphene have been utilized for decades as analgesics. One of the major biotransformation pathways of these drugs occurs through N-demethylation leading to the formation and excretion of normetabolites. Normetabolites generally exhibit longer half-lives than the parent drug leading to accumulation with prolonged use. As part of continuing research efforts to improve monitoring programs of chronic pain patients undergoing opioid treatment, we evaluated the prevalence and relative abundance of normetabolites of buprenorphine, fentanyl, meperidine, methadone, and propoxyphene in patients' urine specimens. Selected sets of specimens were analyzed without prior immunoassay screening by liquid chromatography- tandem mass spectrometry for buprenorphine, fentanyl, meperidine, methadone, propoxyphene, and their respective normetabolites. Limits of quantitation (LOQ) were as follows: buprenorphine, 1 ng/mL; fentanyl, 0.5 ng/mL; meperidine, 50 ng/mL; methadone, 50 ng/mL; and propoxyphene, 50 ng/mL. LOQs for normetabolites were equal to the parent drug with the exception of norbuprenorphine (2.5 ng/mL). The percentage of positive specimens that contained normetabolite (only) ranged from 8.0% for EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine) to 53.1% for norpropoxyphene. Inclusion of the five normetabolites in the test panel produced an increase in detection rates for parent drug use as follows: buprenorphine, 10.0%; fentanyl, 42.1%; meperidine, 98.7%; methadone, 8.7%; and propoxyphene, 113.2%. The authors conclude that testing for synthetic opioid normetabolites enhances the effectiveness of monitoring programs for pain patients.

Original languageEnglish (US)
Pages (from-to)444-449
Number of pages6
JournalJournal of Analytical Toxicology
Volume34
Issue number8
StatePublished - Oct 2010

Fingerprint

Dextropropoxyphene
Buprenorphine
Meperidine
Methadone
Fentanyl
Biomarkers
Chronic Pain
urine
Opioid Analgesics
biomarker
drug
Urine
Monitoring
Liquid chromatography
Testing
Pharmaceutical Preparations
Parents
Mass spectrometry
Screening
immunoassay

ASJC Scopus subject areas

  • Analytical Chemistry
  • Toxicology
  • Health, Toxicology and Mutagenesis
  • Chemical Health and Safety
  • Environmental Chemistry

Cite this

De Priest, A., Heltsley, R., Black, D. L., Cawthon, B., Robert, T., Moser, F., ... Cone, E. J. (2010). Urine drug testing of chronic pain patients. III. normetabolites as biomarkers of synthetic opioid use. Journal of Analytical Toxicology, 34(8), 444-449.

Urine drug testing of chronic pain patients. III. normetabolites as biomarkers of synthetic opioid use. / De Priest, Anne; Heltsley, Rebecca; Black, David L.; Cawthon, Beverly; Robert, Tim; Moser, Frank; Caplan, Yale H.; Cone, Edward J.

In: Journal of Analytical Toxicology, Vol. 34, No. 8, 10.2010, p. 444-449.

Research output: Contribution to journalArticle

De Priest, A, Heltsley, R, Black, DL, Cawthon, B, Robert, T, Moser, F, Caplan, YH & Cone, EJ 2010, 'Urine drug testing of chronic pain patients. III. normetabolites as biomarkers of synthetic opioid use', Journal of Analytical Toxicology, vol. 34, no. 8, pp. 444-449.
De Priest A, Heltsley R, Black DL, Cawthon B, Robert T, Moser F et al. Urine drug testing of chronic pain patients. III. normetabolites as biomarkers of synthetic opioid use. Journal of Analytical Toxicology. 2010 Oct;34(8):444-449.
De Priest, Anne ; Heltsley, Rebecca ; Black, David L. ; Cawthon, Beverly ; Robert, Tim ; Moser, Frank ; Caplan, Yale H. ; Cone, Edward J. / Urine drug testing of chronic pain patients. III. normetabolites as biomarkers of synthetic opioid use. In: Journal of Analytical Toxicology. 2010 ; Vol. 34, No. 8. pp. 444-449.
@article{d89fb5dc1bf4468fa78f5ee20f1a1caf,
title = "Urine drug testing of chronic pain patients. III. normetabolites as biomarkers of synthetic opioid use",
abstract = "Opioids are important therapeutic agents available to patients with moderate to severe pain. The synthetic opioids, buprenorphine, fentanyl, meperidine, methadone, and propoxyphene have been utilized for decades as analgesics. One of the major biotransformation pathways of these drugs occurs through N-demethylation leading to the formation and excretion of normetabolites. Normetabolites generally exhibit longer half-lives than the parent drug leading to accumulation with prolonged use. As part of continuing research efforts to improve monitoring programs of chronic pain patients undergoing opioid treatment, we evaluated the prevalence and relative abundance of normetabolites of buprenorphine, fentanyl, meperidine, methadone, and propoxyphene in patients' urine specimens. Selected sets of specimens were analyzed without prior immunoassay screening by liquid chromatography- tandem mass spectrometry for buprenorphine, fentanyl, meperidine, methadone, propoxyphene, and their respective normetabolites. Limits of quantitation (LOQ) were as follows: buprenorphine, 1 ng/mL; fentanyl, 0.5 ng/mL; meperidine, 50 ng/mL; methadone, 50 ng/mL; and propoxyphene, 50 ng/mL. LOQs for normetabolites were equal to the parent drug with the exception of norbuprenorphine (2.5 ng/mL). The percentage of positive specimens that contained normetabolite (only) ranged from 8.0{\%} for EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine) to 53.1{\%} for norpropoxyphene. Inclusion of the five normetabolites in the test panel produced an increase in detection rates for parent drug use as follows: buprenorphine, 10.0{\%}; fentanyl, 42.1{\%}; meperidine, 98.7{\%}; methadone, 8.7{\%}; and propoxyphene, 113.2{\%}. The authors conclude that testing for synthetic opioid normetabolites enhances the effectiveness of monitoring programs for pain patients.",
author = "{De Priest}, Anne and Rebecca Heltsley and Black, {David L.} and Beverly Cawthon and Tim Robert and Frank Moser and Caplan, {Yale H.} and Cone, {Edward J.}",
year = "2010",
month = "10",
language = "English (US)",
volume = "34",
pages = "444--449",
journal = "Journal of Analytical Toxicology",
issn = "0146-4760",
publisher = "Preston Publications",
number = "8",

}

TY - JOUR

T1 - Urine drug testing of chronic pain patients. III. normetabolites as biomarkers of synthetic opioid use

AU - De Priest, Anne

AU - Heltsley, Rebecca

AU - Black, David L.

AU - Cawthon, Beverly

AU - Robert, Tim

AU - Moser, Frank

AU - Caplan, Yale H.

AU - Cone, Edward J.

PY - 2010/10

Y1 - 2010/10

N2 - Opioids are important therapeutic agents available to patients with moderate to severe pain. The synthetic opioids, buprenorphine, fentanyl, meperidine, methadone, and propoxyphene have been utilized for decades as analgesics. One of the major biotransformation pathways of these drugs occurs through N-demethylation leading to the formation and excretion of normetabolites. Normetabolites generally exhibit longer half-lives than the parent drug leading to accumulation with prolonged use. As part of continuing research efforts to improve monitoring programs of chronic pain patients undergoing opioid treatment, we evaluated the prevalence and relative abundance of normetabolites of buprenorphine, fentanyl, meperidine, methadone, and propoxyphene in patients' urine specimens. Selected sets of specimens were analyzed without prior immunoassay screening by liquid chromatography- tandem mass spectrometry for buprenorphine, fentanyl, meperidine, methadone, propoxyphene, and their respective normetabolites. Limits of quantitation (LOQ) were as follows: buprenorphine, 1 ng/mL; fentanyl, 0.5 ng/mL; meperidine, 50 ng/mL; methadone, 50 ng/mL; and propoxyphene, 50 ng/mL. LOQs for normetabolites were equal to the parent drug with the exception of norbuprenorphine (2.5 ng/mL). The percentage of positive specimens that contained normetabolite (only) ranged from 8.0% for EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine) to 53.1% for norpropoxyphene. Inclusion of the five normetabolites in the test panel produced an increase in detection rates for parent drug use as follows: buprenorphine, 10.0%; fentanyl, 42.1%; meperidine, 98.7%; methadone, 8.7%; and propoxyphene, 113.2%. The authors conclude that testing for synthetic opioid normetabolites enhances the effectiveness of monitoring programs for pain patients.

AB - Opioids are important therapeutic agents available to patients with moderate to severe pain. The synthetic opioids, buprenorphine, fentanyl, meperidine, methadone, and propoxyphene have been utilized for decades as analgesics. One of the major biotransformation pathways of these drugs occurs through N-demethylation leading to the formation and excretion of normetabolites. Normetabolites generally exhibit longer half-lives than the parent drug leading to accumulation with prolonged use. As part of continuing research efforts to improve monitoring programs of chronic pain patients undergoing opioid treatment, we evaluated the prevalence and relative abundance of normetabolites of buprenorphine, fentanyl, meperidine, methadone, and propoxyphene in patients' urine specimens. Selected sets of specimens were analyzed without prior immunoassay screening by liquid chromatography- tandem mass spectrometry for buprenorphine, fentanyl, meperidine, methadone, propoxyphene, and their respective normetabolites. Limits of quantitation (LOQ) were as follows: buprenorphine, 1 ng/mL; fentanyl, 0.5 ng/mL; meperidine, 50 ng/mL; methadone, 50 ng/mL; and propoxyphene, 50 ng/mL. LOQs for normetabolites were equal to the parent drug with the exception of norbuprenorphine (2.5 ng/mL). The percentage of positive specimens that contained normetabolite (only) ranged from 8.0% for EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine) to 53.1% for norpropoxyphene. Inclusion of the five normetabolites in the test panel produced an increase in detection rates for parent drug use as follows: buprenorphine, 10.0%; fentanyl, 42.1%; meperidine, 98.7%; methadone, 8.7%; and propoxyphene, 113.2%. The authors conclude that testing for synthetic opioid normetabolites enhances the effectiveness of monitoring programs for pain patients.

UR - http://www.scopus.com/inward/record.url?scp=79954615172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954615172&partnerID=8YFLogxK

M3 - Article

VL - 34

SP - 444

EP - 449

JO - Journal of Analytical Toxicology

JF - Journal of Analytical Toxicology

SN - 0146-4760

IS - 8

ER -